Sparsentan_DF2, IRBESARTAN, Sparsentan_DF3
021FSGS16010
Phase 3 small_molecule active
Quick answer
Sparsentan_DF2, IRBESARTAN, Sparsentan_DF3 for Focal segmental glomerulosclerosis (FSGS) is a Phase 3 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Travere Therapeutics
- Indication
- Focal segmental glomerulosclerosis (FSGS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active